EDSA News and Press, Edesa Biotech Inc. From 09/20/21

Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...

ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients ER...

Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Data monitoring board recommends continuation to confirmatory Phase 3 study T...

TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Gl...

Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORONTO, ON / ACCESSWIRE / August 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a cl...

TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its bus...

GENEVA, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today announces the appointment of Sean A. MacDonald to the newly-created position of Chief Business O...

Edesa Biotech (EDSA) has expanded patient enrollment to Canada for the final part of a Phase 2b study evaluating its EB01 drug candidate as a monotherapy for chronic Allergic Contact Dermatitis ((Eczema)).The first part of the study was conducted in the United States, where enr...

TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has expanded patient enrollment to Canada for the final part of a Phase 2b study eval...

As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, naproxen and other NSAIDs are effective, but can induce ulceration and bleeding of the digestive tract, with much higher incidence in patients, as noted by An...